Text Size

Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty

This study has been terminated.
(The primary efficacy endpoint was not met)
Sponsor:
Information provided by (Responsible Party):
Lux Biosciences, Inc.
ClinicalTrials.gov Identifier:
NCT00447642
First received: March 13, 2007
Last updated: October 9, 2012
Last verified: October 2012
History of Changes
  Purpose

This study will evaluate the use of LX201 to prevent future graft rejection episodes and/or graft failure in patients who have undergone corneal transplantation and who have recently experienced a rejection episode due to an immune response.


Condition Intervention Phase
Corneal Transplantation
Corneal Graft Rejection
 Drug: LX201
Other: Placebo
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Prevention
Official Title: A Multi-center, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Assess the Efficacy and Safety of LX201 Implantation for the Prevention of Corneal Allograft Rejection Episodes or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Lux Biosciences, Inc.:

Primary Outcome Measures:
  • prevention of corneal allograft rejection or graft failure [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]

Enrollment: 122
Study Start Date: April 2007
Study Completion Date: January 2010
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LX201 0.50 inch implant
LX201 implant contained 30% cyclosporine A by weight and 0.50 inch in length
 Drug: LX201

LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight.

LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant is 0.08 inch wide and 0.04 inch in height. The implants are flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded.
Experimental: LX201 0.75 inch implant
LX201 implant contained 30% cyclosporine A by weight and 0.75 inch by length
 Drug: LX201

LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight.

LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant is 0.08 inch wide and 0.04 inch in height. The implants are flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded.
Placebo Comparator: Placebo 0.75 inch implant
Silicone implant not containing cyclosporine A, 0.75 inch in length
 Other: Placebo
The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A

Detailed Description:

LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight. LX201 is intended for surgical episcleral placement in the eye.

The study was a Phase 2/3, multi-center, placebo-controlled, randomized, parallel-group, dose-ranging study of LX201 for prevention of corneal allograft rejection or graft failure in subjects who have had one or more rejection episodes following penetrating keratoplasty.

After Visit 12 (Week 52), subjects in the USA and India with the implant in the study eye were to be followed for safety at least once per year for a 2 year period or until time of implant removal. In Germany, the implant was to be removed at Week 52 with a 3-month safety follow-up period after removal.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects who, within 6 months prior to study randomization, have experienced 1 or more corneal allograft rejection episodes following penetrating keratoplasty
  • Must be on a stable medical regimen for at least 14 days at the time of randomization into the study
  • Conjunctiva must be suitable for implantation with the study device

Exclusion Criteria:

  • Any condition that would greatly increase the risk of non-rejection graft failure such as Stevens-Johnson syndrome, xerophthalmia or severe exposure keratitis.
  • Schirmer's test ≤ 5 mm in 1 minute.
  • Clinical evidence of limbal stem cell deficiency.
  • History of or active herpes simplex virus keratitis or other acute corneal infection
  • Subjects who have had > 3 failed grafts in the ipsilateral eye
  • Uncontrolled glaucoma as evidenced by an intraocular pressure of > 21 mmHg while on maximal medical therapy
  • Clinically suspected or confirmed ocular lymphoma
  • Treatment with a systemic immunosuppressive regimen within the previous 30 days; systemic prednisone (or its equivalent) of ≤ 10 mg daily is, however, permitted.
  • Any implantable corticosteroid-eluting device (e.g., Retisert™, Posurdex®, Medidur™, I-vation™ triamcinolone acetonide [TA] intravitreal implant)
  • Subjects who periodically require high-dose systemic steroid treatment (e.g., for exacerbation of chronic obstructive pulmonary disease).
  • Subjects who have received treatment with a monoclonal antibody or any other biologic therapy within the previous 90 days or alemtuzumab within the previous 12 months
  • History of herpes zoster or varicella infection within 6 weeks prior to enrollment, or chicken pox exposure within 21 days before enrollment
  • Seropositivity for human immunodeficiency virus (HIV)
  • Previous exposure or known contraindication to administration of cyclosporine
  • Recipients of a solid organ transplant
  • Currently participating in another clinical trial with an investigational agent in the 30 days prior to study participation and/or has not recovered from any reversible effects or side effects of prior investigational agent
  • Currently pregnant or lactating
  • Active, extraocular and/or systemic infection requiring the prolonged or chronic use of antimicrobial agents or the presence of active hepatitis A, B or C
  • Current malignancy or a history of malignancy (within the previous 5 years) except non-metastatic basal or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix that has been treated successfully
  • Active peptic ulcer disease
  • Co-morbid conditions that require immunosuppression
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00447642

  Show 30 Study Locations
Sponsors and Collaborators
Lux Biosciences, Inc.
Investigators
Study Chair: Eddy Anglade, MD Chief Medical Officer, Lux Biosciences, Inc.
  More Information

No publications provided

Responsible Party: Lux Biosciences, Inc.
ClinicalTrials.gov Identifier: NCT00447642     History of Changes
Other Study ID Numbers: LX201-02
Study First Received: March 13, 2007
Last Updated: October 9, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Lux Biosciences, Inc.:
immunology
cornea
allograft
corneal allograft rejection
graft failure

Additional relevant MeSH terms:
Cyclosporins
Cyclosporine
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Immunosuppressive Agents
Immunologic Factors
 Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Therapeutic Uses
Dermatologic Agents
Antirheumatic Agents

ClinicalTrials.gov processed this record on May 22, 2013